Predicting prognosis and optimal timing for surgery using CA 19-9 in patients with pancreatic cancer who underwent FOLFIRINOX-based neoadjuvant therapy: a retrospective single-center cohort study
{{output}}
Purpose: Neoadjuvant therapy (NAT) followed by surgical resection is the standard treatment for borderline resectable pancreatic cancer. The optimal timing for surgery after NAT, however, is unclear. ... ...
